

**ASX ANNOUNCEMENT**

**Allied announces successful result for Coridon's HPV vaccine**

- Successful first study of next HPV vaccine developed by Prof Ian Frazer
- No tumours present in HPV vaccinated mice compared to control

**Brisbane, Australia, 15th November 2012**

Australian biomedical company Allied Healthcare Group (ASX: AHZ) has today announced the successful results of its initial study of a novel HPV (Human Papilloma Virus) vaccine, being developed by its investment company Coridon.

The Coridon project, led by Professor Ian Frazer, is working to develop a therapeutic vaccine which has been designed to combat existing HPV infection and to prevent and treat cancer onset.

Existing HPV vaccines, Gardasil® (marketed by Merck & Co) and Cervarix® (marketed by GlaxoSmithKline) developed by Prof Frazer, are only effective in preventing transmission of the virus which is a common precursor to cervical cancer.

The results from the preclinical study confirm the Coridon vaccine induces an immune response that can protect mice from developing cancer tumours associated with HPV infection.

Immunised animals showed no tumours at the end of the study compared to the control animals, all of which developed large tumours.

"These are very promising results for this program. We are moving another step closer to developing a therapeutic treatment for HPV-associated cervical cancer," said Lee Rodne, Group Managing Director of Allied Healthcare Group.

"Given the wide benefits associated with Professor Frazer's blockbuster vaccines Gardasil and Cervarix, we are very excited by the possibility of developing a vaccine, that can not only prevent infection, but can also stop the development of disease in people that have already been infected."

Coridon's HPV DNA vaccine is designed to target and clear HPV transformed cells and represents a new strategy to protect against cancers caused by existing infections with this virus. These results represent the first steps in proving the effectiveness of our vaccine with the vaccine meeting all expectations to date.

"This finding further confirms through preclinical studies the potential of Coridon's technologies for developing successful immunotherapies" stated Professor Frazer.

Despite the availability of prophylactic vaccines such as Gardasil®, surveys in the US show only approximately 30% of women complete the vaccination schedule required for protection from HPV infection. If proven safe and effective, Coridon could offer an alternative that both protects from HPV infection and reduces associated cancer risk in those already exposed.



"We are developing a platform technology for prevention and treatment of diseases via next generation vaccines. These results indicate that the technology can be applied to a number of diseases," said Neil Finlayson, CEO of Coridon.

HPV is one of the most common sexually transmitted diseases in the world and, as well as cervical cancer, is associated with a variety of anogenital cancers and head and neck cancer. Cervical cancer is the second largest cause of cancer deaths in women worldwide. Globally, this equates to 510,000 cases per year, and about 288,000, deaths according to WHO.

In the USA, the Centers for Disease Control and Prevention estimates that 26.8% of 14-59 year old females are currently infected and over 25 million people have HPV infection and another 6.2 million people will become infected each year.

According to the US National Cancer Institute at the National Institutes of Health, in 2009, there were 11,270 new cases and 4,070 deaths from cervical cancer in the USA. Medicare reports that approximately \$1.7 billion is spent in the USA each year to treat cervical cancer. The two currently used HPV vaccines, which are targeted at young women prior to onset of sexual activity, generate in excess of \$1.5Bn in sales annually.

In the current study, groups of 10 mice were vaccinated intradermally with the Coridon HPV mixed DNA vaccine and compared to no vaccination or control animal model vaccine consisting of E7 protein with adjuvant.

After two immunisations 3 weeks apart, tumour cells were implanted and tumour formation was monitored. Mice receiving no vaccine developed large tumours whereas all mice immunised with Coridon's DNA vaccine or the positive control survived with no tumours to the completion of the study.

The Company's other DNA vaccine candidate, to treat Herpes Simplex Virus (HSV) infection is progressing well, with manufacturing and preclinical studies nearing completion and the Phase I scheduled to begin in the next few months.

**For more information, please contact:**

Dr Julian Chick, Chief Operating Officer Allied Healthcare Group Tel: +61 3 9620 5454

**Media:**

Shevaun Cooper  
Buchan Consulting  
+61 3 9866 4722  
[scooper@buchanwe.com.au](mailto:scooper@buchanwe.com.au)



ABN 35 088 221 078

Level 1, 197 Adelaide Terrace  
Perth Western Australia 6000

PO Box 6879 East Perth  
Western Australia 6892

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199

E [info@alliedhealthcaregroup.com.au](mailto:info@alliedhealthcaregroup.com.au)

[www.alliedhealthcaregroup.com.au](http://www.alliedhealthcaregroup.com.au)

## About Allied Healthcare Group Limited

Allied Healthcare Group Limited (ASX: AHZ) is a diversified healthcare company focused on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow its product and service offerings and expanding revenues from its existing profitable medical Sales and Marketing division. The Company has assets from research & development, clinical development as well as sales and marketing of medical devices and technologies.

Allied Healthcare Group is in the process of commercialising its innovative tissue engineering technology for regenerative medicine. Allied also has major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programs target disease with significant global potential like herpes and Human Papilloma Virus.

Further information on the Company can be found on [www.alliedhealthcaregroup.com.au](http://www.alliedhealthcaregroup.com.au).



ABN 35 088 221 078

Level 1, 197 Adelaide Terrace  
Perth Western Australia 6000

PO Box 6879 East Perth  
Western Australia 6892

T +61 (0)8 9266 0100

F +61 (0)8 9266 0199

E [info@alliedhealthcaregroup.com.au](mailto:info@alliedhealthcaregroup.com.au)

[www.alliedhealthcaregroup.com.au](http://www.alliedhealthcaregroup.com.au)